DNA-Matched drugs may outperform standard care for advanced cancers
NCT ID NCT07346209
First seen Jan 27, 2026 · Last updated May 22, 2026 · Updated 16 times
Summary
This study looks at whether drugs chosen based on a patient's tumor DNA mutations can delay cancer growth longer than standard treatments. About 280 adults with metastatic or unresectable solid cancers will either receive matched drugs or standard care. Participants visit the clinic every two months for checkups and scans to track how well the treatment works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, San Diego
La Jolla, California, 92093, United States
Conditions
Explore the condition pages connected to this study.